PGRMC1 as a potential biomarker of breast cancer risk for menopausal hormone therapy
10.3969/j.issn.1006-7795.2025.04.001
- VernacularTitle:PGRMC1:绝经激素治疗中乳腺癌风险预测的潜在生物学标志物
- Author:
Yuejiao WANG
1
;
Xiangyan RUAN
;
Muqing GU
;
Yun WEI
;
Yuwei GUAN
;
Yue ZHAO
;
O.Mueck ALFRED
Author Information
1. 首都医科大学附属北京妇产医院/北京妇幼保健院内分泌科,北京 100026
- Publication Type:Journal Article
- Keywords:
progesterone receptor membrane component 1;
progesterone receptor membrane component 1(PGRMC1);
menopausal hormone therapy;
breast cancer risk;
breast cancer;
hormone safety
- From:
Journal of Capital Medical University
2025;46(4):589-593
- CountryChina
- Language:Chinese
-
Abstract:
Progesterone receptor membrane component 1(PGRMC1)is closely related to hormone therapy which belongs to the membrane-associated progesterone receptor(MAPR)family.A large number of in vitro experiments,in vivo animal experiments,clinical samples of breast cancer patients and blood studies showed that all synthetic progesterone(excluding natural progesterone and dydrogesterone)can promote the rapid proliferation of breast cancer cells overexpressing PGRMC1.In patients with breast cancer,PGRMC1 is significantly negatively correlated with tumor grade and prognosis,and PGRMC1 level in blood is positively correlated with PGRMC1 expression in breast cancer tissues,and PGRMC1 is superior to traditional tumor markers such as carcinoembryonic antigen(CEA),carbohydrate antigen(CA125),and CA153 in predicting early breast cancer.Therefore,PGRMC1 may serve as a predictive marker for identifying an elevated risk of breast cancer associated with menopausal hormone replacement therapy.
